Anna K Blakney
Overview
Explore the profile of Anna K Blakney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen S, Wang S, Liao S, Blakney A
ACS Bio Med Chem Au
. 2025 Feb;
5(1):154-165.
PMID: 39990935
The current rapid advancement in ribonucleic acid (RNA) therapeutics research depends on innovations in drug delivery, especially the development of a lipid-nanoparticle (LNP)-based system. The conventional LNP formulation typically contains...
2.
Maine C, Miyake-Stoner S, Spasova D, Picarda G, Chou A, Brand E, et al.
Nat Commun
. 2025 Jan;
16(1):456.
PMID: 39774967
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile....
3.
Casmil I, Bathula N, Huang C, Wayne C, Cairns E, Friesen J, et al.
Mol Ther
. 2025 Jan;
33(2):514-528.
PMID: 39741413
Self-amplifying RNA (saRNA) vectors are a next-generation RNA technology that extends the expression of heterologous genes. Clinical trials have shown the dose-sparing capacity of saRNA vectors in a vaccine context...
4.
Liao S, Wang S, Wadhwa A, Birkenshaw A, Fox K, Cheng M, et al.
ACS Appl Mater Interfaces
. 2024 Dec;
17(2):3097-3105.
PMID: 39737597
When formulating mRNA into lipid nanoparticles (LNP), various copy numbers of mRNA are encapsulated, leading to a distribution of mRNA loading levels within the LNPs. It is unclear whether the...
5.
Kitandwe P, Rogers P, Hu K, Nayebare O, Blakney A, McKay P, et al.
Vaccines (Basel)
. 2024 Oct;
12(10).
PMID: 39460255
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that causes high fetal and neonatal mortality rates in ruminants and sometimes severe to fatal complications like encephalitis and hemorrhagic fever...
6.
Bathula N, Friesen J, Casmil I, Wayne C, Liao S, Soriano S, et al.
J Control Release
. 2024 Aug;
374:28-38.
PMID: 39097193
Self-amplifying RNA (saRNA) is a next-generation RNA platform derived from an alphavirus that enables replication in host cytosol, offering a promising shift from traditional messenger RNA (mRNA) therapies by enabling...
7.
8.
Chen Y, Lin X, Liu X, Liu Y, Bui-Le L, Blakney A, et al.
Biomacromolecules
. 2024 Apr;
25(5):2965-2972.
PMID: 38682378
Nucleic acid therapeutics have attracted recent attention as promising preventative solutions for a broad range of diseases. Nonviral delivery vectors, such as cationic polymers, improve the cellular uptake of nucleic...
9.
Wayne C, Blakney A
Cell
. 2024 Apr;
187(8):1822-1822.e1.
PMID: 38608649
In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and...
10.
G Popova P, Chen S, Liao S, Sadarangani M, Blakney A
Adv Drug Deliv Rev
. 2024 Mar;
208:115292.
PMID: 38522725
Vaccination is one of the most successful measures in modern medicine to combat diseases, especially infectious diseases, and saves millions of lives every year. Vaccine design and development remains critical...